Polypharmacy: should we or shouldn’t we?

Much has been written recently in The Psychiatrist about how psychiatrists should manage antipsychotic polypharmacy. Taylor[1][1] could hardly be more emphatic: ‘evidence supporting antipsychotic polypharmacy has, if anything, diminished and evidence suggesting or demonstrating harm has grown’.